CardioVascular BioTherapeutics (fka CVBT)

[johnnyblades2001]

I disagree that the trials need to be completed prior to the stock relisting. There are plenty of development stage biotechs that are listed while neck deep in trials.....

BUT there does need to be disclosures around adequate funding, product supply, enrollment, cohorts, CRO and timeline. Investors need to be able to see via financial disclosures and public press releases that the company has the means, the resources, and the right partners to execute on the trials.

OTHERWISE, yes....a relisting without any of the above would not hold its value...especially with so many long term shareholders that are probably looking to monetize their investments.

The only thing that will mitigate the pent up demand to sell is releasing sufficient news to attract enough new buyers to more than offset the selling.